PubRank

Roy S Herbst

Author PubWeight™ 201.83‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 12.35
2 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005 9.95
3 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004 8.83
4 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 7.87
5 The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011 7.57
6 KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007 4.45
7 Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003 4.07
8 Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005 4.04
9 An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2012 3.48
10 American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014 3.20
11 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005 3.12
12 To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008 3.05
13 Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008 2.85
14 Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012 2.79
15 Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007 2.77
16 Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials 2008 2.71
17 Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008 2.68
18 Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005 2.36
19 Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006 2.32
20 [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005 2.30
21 Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011 2.25
22 Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011 2.21
23 Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007 2.16
24 Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005 2.12
25 Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 2009 2.06
26 Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009 1.87
27 Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 2010 1.78
28 Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008 1.74
29 Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. J Clin Oncol 2012 1.74
30 Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. J Clin Oncol 2002 1.64
31 Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2006 1.64
32 Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 2003 1.62
33 Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res 2013 1.62
34 Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 2010 1.59
35 Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 2003 1.55
36 Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 2011 1.52
37 A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012 1.43
38 Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clin Cancer Res 2003 1.38
39 A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010 1.34
40 Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007 1.32
41 CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 2012 1.32
42 Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004 1.32
43 Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008 1.29
44 Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008 1.29
45 VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2009 1.24
46 Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005 1.19
47 Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002 1.18
48 Opening up to precompetitive collaboration. Sci Transl Med 2010 1.18
49 Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 2008 1.17
50 A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010 1.16
51 Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004 1.14
52 Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 2007 1.13
53 Molecular signatures of lung cancer--toward personalized therapy. N Engl J Med 2007 1.12
54 Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 2005 1.10
55 Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. J Nucl Med 2008 1.08
56 Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007 1.07
57 Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005 1.05
58 Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res 2011 1.05
59 Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res 2012 1.01
60 Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 2012 1.01
61 Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer 2005 1.01
62 Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 2006 1.01
63 Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol 2010 1.00
64 Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res 2012 1.00
65 B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J 2014 1.00
66 Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 2007 1.00
67 Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 2005 1.00
68 Tobacco and cancer: an American Association for Cancer Research policy statement. Cancer Res 2010 0.99
69 Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004 0.98
70 Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther 2002 0.98
71 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
72 Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 2005 0.96
73 Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer 2009 0.96
74 A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009 0.96
75 Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 2006 0.95
76 Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 2013 0.95
77 Phase I participants' views of quality of life and trial participation burdens. Support Care Cancer 2007 0.92
78 Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer 2011 0.92
79 Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 2004 0.91
80 Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004 0.91
81 Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest 2015 0.90
82 Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004 0.89
83 Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res 2004 0.88
84 Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nat Clin Pract Oncol 2009 0.88
85 Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002 0.87
86 Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008 0.87
87 Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 2010 0.87
88 Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop. Oncologist 2013 0.87
89 "Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. Clin Cancer Res 2014 0.86
90 Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol 2013 0.85
91 Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin Cancer Res 2004 0.84
92 The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets 2014 0.84
93 Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 2004 0.84
94 Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. J Clin Oncol 2012 0.83
95 Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 2007 0.83
96 Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. J Comput Assist Tomogr 2009 0.83
97 Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer. J Thorac Oncol 2013 0.83
98 Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006 0.82
99 Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest 2016 0.82
100 Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol 2013 0.81
101 Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011 0.81
102 Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 2007 0.81
103 Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am 2002 0.80
104 Targeted drug delivery strategies to treat lung metastasis. Expert Opin Drug Deliv 2009 0.80
105 Use of novel second-line targeted therapies in non-small cell lung cancer. Semin Oncol 2006 0.79
106 Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer 2004 0.79
107 Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men? Clin Lung Cancer 2008 0.79
108 Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer 2005 0.78
109 Antiangiogenic tumor therapy. Biotechniques 2003 0.78
110 Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer 2013 0.78
111 Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology (Williston Park) 2004 0.78
112 Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol 2008 0.78
113 Multitargeted inhibitors in lung cancer: new clinical data. Clin Lung Cancer 2008 0.77
114 Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol 2010 0.77
115 Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol 2008 0.77
116 Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. Clin Lung Cancer 2004 0.76
117 Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study). J Clin Oncol 2012 0.76
118 Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016 0.76
119 Angiogenesis and lung cancer: implications for prognosis and treatment. Lancet Oncol 2007 0.75
120 Angiogenesis, metastasis, and lung cancer. An overview. Methods Mol Med 2003 0.75
121 A step towards treating KRAS-mutant NSCLC. Lancet Oncol 2012 0.75
122 Surgery: Future directions in multimodality therapy for NSCLC. Nat Rev Clin Oncol 2010 0.75
123 What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer? Nat Clin Pract Oncol 2005 0.75
124 Future directions of monoclonal antibody use in personalized lung cancer therapy. Oncology (Williston Park) 2010 0.75
125 EGFR expression and the flexibility of FLEX. Lancet Oncol 2011 0.75
126 Molecular targeted therapy for lung cancer. Lancet 2005 0.75
127 [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi 2010 0.75
128 From the Guest Editors: Progress and Future Directions for the Treatment of Advanced Lung Cancer. Cancer J 2015 0.75
129 Who should go first in trials with scarce agents? The views of potential participants. IRB 2007 0.75
130 In vitro and in vivo assays for the proliferative and vascular permeabilization activities of vascular endothelial growth factor (VEGF) and its receptor. Methods Mol Med 2003 0.75
131 The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. Semin Oncol Nurs 2002 0.75
132 New targets for the treatment of advanced non-small cell lung cancer. Cancer Chemother Biol Response Modif 2002 0.75
133 Integration of targeted therapies in gemcitabine chemotherapy regimens. Clin Lung Cancer 2003 0.75
134 Angiogenesis inhibitors in lung cancer. Curr Oncol Rep 2002 0.75
135 Miscellaneous agents. J Thorac Oncol 2012 0.75
136 Current and future strategies for antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 2008 0.75